Perioperative Pembro Approved to Up Chance of HNSCC Cure

The FDA has approved a before and after surgery regimen for pembrolizumab to improve outcomes in resectable locally-advanced head and neck squamous cell carcinoma (HNSCC).
Specifically, the new approval is for HNSCC tumors that express PD-L1, with pembrolizumab as a single agent in the neoadjuvant setting, followed by radiation plus/minus cisplatin after surgery, and continuing as a single agent for maintenance.
FDA said the approval is the first for HNSCC in 6 years, but it is also another approval for a perioperative immunotherapy cancer regimen.
Oncologists and the agency have been frustrated that company trials don't include an arm to answer the question of if immunotherapy helps both before and after surgery, of if one or the other is enough.
Even so, Barbara Burtness, MD, a head and neck oncologist at Yale University, Connecticut, told Medscape Medical News that she'll offer the new pembrolizumab regimen to resectable patients given the strength of pembrolizumab's approval trial, KEYNOTE-689, because it offers the chance of a cure when tumors are resectable.
'Many of us think it's the new standard of care,' she told Medscape.
KEYNOTE-689 was a multicenter, open-label trial that included 682 patients with resectable stage III-IVa disease whose tumors had a PD-L1 combined positive score of at least 1. Approval was based on the 682 patients, not the total population of 714.
Half the subjects were randomized to the current standard of care: upfront surgery followed by radiotherapy with or without cisplatin. The other half were randomized to pembrolizumab add-on: 200 mg pembrolizumab every 3 weeks for two cycles before surgery, then pembrolizumab 200 mg every 3 weeks for three cycles afterwards with radiotherapy plus/minus cisplatin, followed by pembrolizumab at the same dose every 3 weeks for 12 cycles as maintenance.
Cisplatin was added after surgery if patients were at high risk for recurrence, meaning that tumor removal was not complete or patients had spread beyond their lymph nodes.
Median event-free survival was 59.7 months with pembrolizumab vs 29.6 months without it (hazard ratio, 0.70; P =.00140). Overall survival was immature, but there was no decrease with pembrolizumab add-on.
There were no new safety signals in the trial. Pembrolizumab labeling warns of immune-mediated adverse events, infusion-related reactions, and embryo-fetal toxicity; 1.4% of pembrolizumab subjects in KEYNOTE-689 were not able to have surgery because of side effects.
FDA noted pembrolizumab should be administered before chemotherapy when given on the same day.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Newsweek

an hour ago

• Newsweek

How Animal Testing in US Could Be Transformed Under Trump

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Millions of animals each year are killed in U.S. laboratories as part of medical training and chemical, food, drug and cosmetic testing, according to the non-profit animal rights organization People for the Ethical Treatment of Animals (PETA). For many animals held captive for research, including a huge range of species from dogs, cats and hamsters to elephants, dolphins and many other species, pain is "not minimized," U.S. Department of Agriculture data shows. The issue of animal testing is something most Americans agree on: it needs to change and gradually be stopped. A Morning Consult poll conducted at the end of last year found that 80 percent of the 2,205 participants either agreed or strongly agreed with the statement: "The US government should commit to a plan to phase out experiments on animals." Since President Donald Trump began his second term, his administration has been making moves to transform and reduce animal testing in country, although the question remains as to whether it will be enough to spare many more animals from pain and suffering this year. Animal Testing In US Could Be Transformed Animal Testing In US Could Be Transformed Photo-illustration by Newsweek/Getty/Canva What Is The Trump Administration Doing About It? There have been various steps taken in different federal agencies to tackle the issue of animal testing since Trump was sworn in on January 20. In April, the Food and Drug Administration (FDA) announced it was "taking a groundbreaking step to advance public health by replacing animal testing in the development of monoclonal antibody therapies and other drugs with more effective, human-relevant methods." The FDA said that its animal testing requirement will be "reduced, refined, or potentially replaced" with a range of approaches, including artificial intelligence-based models, known as New Approach Methodologies or NAMs data. A Department of Health and Human Services (HHS) official told Newsweek: "The agency is paving the way for faster, safer, and more cost-effective treatments for American patients. "As we restore the agency's commitment to gold-standard science and integrity, this shift will help accelerate cures, lower drug prices, and reaffirm U.S. leadership in ethical, modern science." The National Institutes of Health (NIH) announced it was "adopting a new initiative to expand innovative, human-based science while reducing animal use in research," in alignment with the FDA's initiative. The agency said that while "traditional animal models continue to be vital to advancing scientific knowledge," new and emerging technologies could act as alternative methods, either alone or in combination with animal models. The NIH Office of Extramural Research told Newsweek it was "committed to transparently assessing where animal use can be reduced or eliminated by transitioning to [new approach methodologies (NAMs)]." "Areas where research using animals is currently necessary represent high-priority opportunities for investment in NAMs," the agency added. It added that it will "further its efforts to coordinate agency-wide efforts to develop, validate, and scale the use of NAMs across the agency's biomedical research portfolio and facilitate interagency coordination and regulatory translation for public health protection." During Trump's first term, the Environmental Protection Agency (EPA) signed a directive to "prioritize efforts to reduce animal testing and committed to reducing testing on mammals by 30 percent by 2025 and to eliminate it completely by 2035," an EPA spokesperson told Newsweek. Although, the spokesperson added: "the Biden Administration halted progress on these efforts by delaying compliance deadlines." As a member of the House, Lee Zeldin, the EPA's current administrator, co-sponsored various bills during Trump's first term regarding animal cruelty, covering issues such as phasing out animal-based testing for cosmetic products; ending taxpayer funding for painful experiments on dogs at the Department of Veteran Affairs; empowering federal law enforcement to prosecute animal abuse cases that cross state lines; and others, the spokesperson said. What The Experts Think Needs To Be Done The Trump administration's efforts to tackle the issue of animal testing appear to be a step in the right direction, according to experts who spoke with Newsweek. "I was pleasantly surprised and quite frankly a bit shocked to read the simultaneous announcements by the NIH and the FDA regarding a new emphasis on the use of alternatives to animals," Jeffrey Morgan, a professor of pathology and laboratory medicine at Brown University in Rhode Island, told Newsweek. Morgan, who is also the director of the Center for Alternatives to Animals in Testing at Brown University, said that both agencies are moving together in the same direction on the issue "sends a unified and very powerful message to the research and biotech communities." He added that the announcements showed "a major acknowledgement of the limitations of the use of animals in research and testing." "What is especially exciting is that the NIH announcement will encourage the entry of new investigators into the field, further accelerating innovation in alternatives with exciting impacts for both discovery and applied research across all diseases," he said. He added that the FDA announcement and its emphasis on a new regulatory science that embraces data from alternatives was "equally exciting." "The demands of this new regulatory science will likewise accelerate innovation because it will establish the much-needed regulatory framework for the rigorous evaluation of data from alternatives," he said. While the administration's initiatives to shift research away from animal testing is heading in the right direction, its policies are "overdue," Dr. Thomas Hartung, a professor in the department of environmental health and engineering at Johns Hopkins Bloomberg School of Public Health, Maryland, told Newsweek. "The animal tests for safety were introduced more than 50 years ago. There is no other area of science where we do not adapt to scientific progress," he said. Hartung added that animal "testing takes too long and is too expensive to really provide the safety consumers want." He said that running animal tests for new chemicals can cost millions and take years in some cases. "Nobody can wait that long, even if they can afford the testing costs," he said. Hartung also believes the shifts in the industry to reduce animal testing have been "coming for a while," as over the last two decades, America's opposition to animal use in medical research has been increasing. "The alignment of FDA and NIH really makes the difference now, which I think is evidence of a strong relationship of their leaderships," he said. Yet in order to make a real difference, Hartung said clear deadlines are key to show that "this is not just lip service." He also said that he thought "the transformative nature of artificial intelligence in this field is not fully acknowledged." "We also need an objective framework for change to better science, such as the evidence-based toxicology approach," he said.

Medscape

2 hours ago

• Medscape

Fast Five Quiz: Alcohol Use Disorder

Alcohol use disorder remains a significant public health challenge in the United States, affecting more than 29 million individuals and contributing to more than 140,000 deaths each year. Despite its high prevalence and devastating health consequences, alcohol use disorder often goes underdiagnosed and undertreated. A widely accepted heuristic framework conceptualizes alcohol use disorder as a 3-stage cycle, binge/intoxication, withdrawal/negative affect, and preoccupation/anticipation, offering clinicians a lens through which to understand its complex neurobiological underpinnings and diverse clinical presentations. Although effective behavioral therapies and several US Food and Drug Administration-approved medications are available for the treatment of alcohol use disorder, these interventions remain markedly underused, contributing to a substantial treatment gap. How much do you know about alcohol misuse and alcohol use disorder? Test your knowledge with this quick quiz. Alcohol misuse in alcohol use disorder can vary, from a pattern of intermittent episodes of binge drinking, to a pattern of prolonged heavy drinking over longer periods of time, to a continual drinking pattern due to fear of alcohol withdrawal. A heavy drinking day is defined as consuming 4 or more drinks for females and 5 or more drinks for males in a single day. In the United States, a standard drink is defined as 12 oz of beer, 5 oz of wine, and 1.5 oz of a distilled beverage. This definition helps identify patterns of alcohol misuse that might indicate alcohol use disorder. Learn more about alcoholism guidelines. Alcohol use disorder is more common in males, although the gap is narrowing. Although males are more likely to engage in frequent and heavy consumption, have a greater consumption of spirits, and experience higher rates of alcohol use mortality, females are at greater risk for certain health complications from alcohol, such as liver damage and experiencing higher blood alcohol concentrations at the same level of intake. Learn more about alcoholism presentation. The most frequent central nervous system consequence of persistent alcohol consumption is alcoholic cerebellar degeneration. This condition results from alcohol toxicity leading to damage of the cerebellum, the brain area responsible for coordination and balance. It commonly presents with gait instability, and balance problems, affecting 10%-25% of individuals with chronic alcohol use. Wernicke's encephalopathy is an acute, reversible condition caused by thiamine deficiency; it is not the most frequent long-term central nervous system consequence of alcohol consumption. Korsakoff syndrome is a chronic neuropsychiatric disorder that often follows untreated Wernicke's encephalopathy and is caused by malnutrition in combination with prolonged drinking. Although chronic alcohol use can lead to alcohol-related dementia, it occurs less frequently than alcoholic cerebellar degeneration. Learn more about Wernicke-Korsakoff syndrome. Alcoholic polyneuropathy, caused by prolonged alcohol use and often associated with nutritional deficiencies like thiamine deficiency, typically presents as a symmetrical sensory neuropathy. Females have a greater rate of alcoholic polyneuropathy. The most common symptoms of alcoholic polyneuropathy are ataxia, pain, and paresthesia. Other frequent symptoms include burning pain in the arms, soles of the feet and toes, and cramping in the calves and hands. Skin alterations do occur in alcoholic polyneuropathy, but they are considered secondary or less common symptoms compared with the hallmark neurological signs. The muscle weakness seen in alcoholic polyneuropathy primarily affects distal muscles, like the feet and hands. Hair loss can happen as a minor trophic change, but it is not a defining or common symptom of alcoholic polyneuropathy. Learn more about alcoholic neuropathy. Benzodiazepines are the recommended class of medication for treating alcohol withdrawal syndrome because they are effective in preventing severe complications of alcohol withdrawal syndrome, such as seizures and delirium tremens, and are considered the criterion standard treatment due to their fast onset, long duration, and safety profile. Selective serotonin reuptake inhibitors do not target the GABAergic or glutamatergic systems involved in alcohol withdrawal syndrome, making them ineffective for managing withdrawal symptoms. Beta-blockers can help control some autonomic symptoms like tremors or tachycardia but do not prevent seizures or delirium tremens, so they are not appropriate as primary treatment. N-methyl-D-aspartate receptor antagonists can modulate glutamate activity but lack enough evidence to be first-line therapy for alcohol withdrawal syndrome. Learn more about alcohol withdrawal syndrome.

Business Insider

6 hours ago

• Business Insider

Incyte announces FDA extends review period for Opzelura sNDA

The company states: 'Incyte (INCY) announced that the FDA has extended the review period for the supplemental New Drug Application, sNDA, for ruxolitinib cream, Opzelura, a topical Janus kinase inhibitor, for the treatment of children 2-11 years old with mild to moderate atopic dermatitis. The PDUFA action date has been extended by three months to September 19, 2025. The FDA extended the PDUFA action date to allow time to review additional chemistry, manufacturing and controls data on the 0.75% strength submitted by Incyte in response to a recent FDA information request.' Steven Stein, M.D., Chief Medical Officer, Incyte stated: 'We are confident in the potential of ruxolitinib cream to become an important non-steroidal, topical treatment option for pediatric patients with atopic dermatitis and we will continue to work closely with the FDA to ensure the Agency has all of the information needed to complete its review.' Confident Investing Starts Here: